Lilly said it is engaging in active dialogue with the Indian government and regulatory authorities to donate bamlanivimab and etesevimab in order to speed up access and provide treatment options for patients with Covid-19. The drugs together have been authorised under emergency use authorisation in the United States and select European Union countries for treatment of mild to moderate Covid-19.